Sfoglia per Autore
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP
2009 Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G.
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients
2009 Palandri F; Ottaviani E; Salmi F; Catani L; Polverelli N; Fiacchini M; Martinelli G; Baccarani M; Vianelli N.
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience
2009 Palandri F; Derenzini E; Ottaviani E; Polverelli N; Catani L; Salmi F; Sabattini E; Bacci F; Zinzani PL; Baccarani M; Vianelli N.
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
2009 Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G.
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
2009 Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party.
Response definitions and European Leukemianet Management recommendations.
2009 Baccarani M; Castagnetti F; Gugliotta G; Palandri F; Soverini S
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
2009 Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; Rosti G; Baccarani M.
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
2009 Palandri F; Castagnetti F; Alimena G; Testoni N; Breccia M; Luatti S; Rege-Cambrin G; Stagno F; Specchia G; Martino B; Levato L; Merante S; Liberati AM; Pane F; Saglio G; Alberti D; Martinelli G; Baccarani M; Rosti G.
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy
2009 Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N.
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
2009 Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G.
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
2009 Palandri F; Testoni N; Luatti S; Marzocchi G; Baldazzi C; Stacchini M; Castagnetti F; Breccia M; Specchia G; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G.
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
2009 Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N.
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib
2010 Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G.
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis
2010 Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients.
2010 Palandri F; Polverelli N; Ottaviani E; Castagnetti F; Baccarani M; Vianelli N.
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison.
2010 Rosti G; Castagnetti F; Gugliotta G; Palandri F; Martinelli G; Baccarani M.
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
2010 Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients.
2011 Durante, S; Terragna, C; Astolfi, A; Palandri, F; Castagnetti, F; Testoni, N; Amabile, M; Iacobucci, I; Soverini, S; Alimena, G; Breccia, M; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Martinelli, G
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.
2011 Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Specchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N.
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study
2011 Palandri F.; Polverelli N.; Catani L.; Ottaviani E.; Baccarani M.; Vianelli N.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP | Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Re...ge Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients | Palandri F; Ottaviani E; Salmi F; Catani L; Polverelli N; Fiacchini M; Martinelli G; Baccarani M;... Vianelli N. | 2009-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience |
Palandri F; Derenzini E; Ottaviani E; Polverelli N; Catani L; Salmi F; Sabattini E; Bacci F; Zin...zani PL; Baccarani M; Vianelli N. |
2009-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response | Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Re...ge-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. | Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava ...C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Response definitions and European Leukemianet Management recommendations. | Baccarani M; Castagnetti F; Gugliotta G; Palandri F; Soverini S | 2009-01-01 | BAILLIERE'S BEST PRACTICE IN CLINICAL HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure | Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; ...Rosti G; Baccarani M. | 2009-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up | Palandri F; Castagnetti F; Alimena G; Testoni N; Breccia M; Luatti S; Rege-Cambrin G; Stagno F; S...pecchia G; Martino B; Levato L; Merante S; Liberati AM; Pane F; Saglio G; Alberti D; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy | Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; ...Baccarani M; Testoni N. | 2009-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. | Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de... Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. | Palandri F; Testoni N; Luatti S; Marzocchi G; Baldazzi C; Stacchini M; Castagnetti F; Breccia M; ...Specchia G; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. | Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucc...hesi A; Baccarani M; Vianelli N. | 2009-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib | Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle ...V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G. | 2010-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis |
Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo... A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G |
2010-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. | Palandri F; Polverelli N; Ottaviani E; Castagnetti F; Baccarani M; Vianelli N. | 2010-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. | Rosti G; Castagnetti F; Gugliotta G; Palandri F; Martinelli G; Baccarani M. | 2010-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. | Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N...; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M | 2010-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. | Durante, S; Terragna, C; Astolfi, A; Palandri, F; Castagnetti, F; Testoni, N; Amabile, M; Iacobuc...ci, I; Soverini, S; Alimena, G; Breccia, M; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Martinelli, G | 2011-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. | Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Spe...cchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study | Palandri F.; Polverelli N.; Catani L.; Ottaviani E.; Baccarani M.; Vianelli N. | 2011-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile